Alirocumab and Cemiplimab
PRO00111111
Phase 2 other active
Quick answer
Alirocumab and Cemiplimab for Non-small Cell Lung Cancer (NSCLC) is a Phase 2 program (other) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- other
- Status
- active